Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sonablate to undergo prostate cancer trials in US:

This article was originally published in Clinica

Executive Summary

US researchers are to begin a clinical trial of Misonix' high intensity ultrasound (HIFU) treatment for prostate cancer, under an investigational exemption device from the FDA. The company's Sonablate 500 system will be used to treat around 40 patients at two sites. The HIFU technology can destroy deep-seated tissue by rapidly elevating the temperature in a precise focal zone, without affecting the intervening tissue and without ionisation effects, claims the Farmingdale, New York company. The device is currently in phase III US trials for the treatment of benign prostatic hyperplasia.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT075492

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel